Central to this finding is the protein ubiquitin, traditionally known for its role in tagging damaged or unnecessary proteins within cells for degradation and recycling. For over fifty years, the scientific consensus firmly held that ubiquitin’s function was confined to proteins alone. However, the novel research spearheaded by WEHI’s Ubiquitin Signalling Division has demonstrated that ubiquitin can directly attach itself to glycogen—a glucose polymer and non-protein molecule—revolutionizing our understanding of cellular sugar management.

The study introduces a sophisticated biochemical pathway in which ubiquitin tags glycogen molecules, effectively regulating their breakdown and storage within cells. This previously unknown layer of control adds complexity to the classic glycogen metabolism pathway taught in biology and medical schools worldwide. When an organism requires energy, ubiquitin’s increased tagging of glycogen correlates with enhanced glycogen depletion, suggesting that ubiquitination serves as an on-demand regulatory switch governing glucose availability.

Key to this revelation was the development of NoPro-clipping, an innovative technique created by the research team, including Dr. Simon Cobbold, Professor David Komander, and Marco Jochem. This method, combined with advanced mass spectrometry technology, allows for the unprecedented detection of ubiquitination on non-protein molecules such as glycogen, a feat previously thought impossible. NoPro-clipping acts like a molecular ‘magnifying glass,’ revealing ubiquitin’s role on a vast array of cellular metabolites that have until now eluded scientific scrutiny.

Beyond glycogen, this method uncovered ubiquitination events on other metabolites like glycerol and spermine, reshaping the landscape of ubiquitin biology and suggesting a much broader functional repertoire for ubiquitin than ever imagined. The implications are profound: ubiquitin is no longer a mere cellular waste-tagging agent but also a critical regulator of metabolism and energy homeostasis.

The physiological relevance of glycogen ubiquitination was vividly demonstrated in animal models. By examining liver tissues from mice in fed and fasted states, the researchers observed dynamic fluctuations in ubiquitin tagging corresponding with glycogen levels. During fasting, when energy demands rise, ubiquitin tags on glycogen increased markedly, promoting glycogen degradation to release glucose. This dynamic modulation highlights ubiquitination’s role as a pivotal metabolic control mechanism.

Clinically, this discovery carries significant promise. Glycogen Storage Diseases (GSD), a family of rare genetic disorders marked by defective glycogen metabolism, currently lack effective treatments. These conditions cause debilitating symptoms due to the improper accumulation or utilization of glycogen. The newfound ubiquitin-based regulatory mechanism offers a tantalizing target for therapeutic intervention, potentially allowing direct modulation of glycogen stores within cells.

Moreover, common metabolic diseases such as diabetes, obesity, and heart disease are frequently associated with excessive glycogen accumulation. Existing drugs like Ozempic primarily influence blood sugar levels indirectly, through hormonal pathways. By contrast, therapies developed from this research could act directly on glycogen molecules, potentially providing more effective control over the root cause of these diseases.

Professor Komander emphasized the paradigm-shifting nature of this work, noting that biology textbooks may soon require rewriting. The identification of a ubiquitin-regulated glycogen metabolism pathway not only deepens fundamental biological understanding but also marks the advent of a new frontier in metabolism research. “This adds a completely new chapter to a book we thought was finished,” he remarked, underscoring the transformative impact of this knowledge.

PhD candidate Marco Jochem reflected on the versatility and potential of the NoPro-clipping technique. Its ability to detect ubiquitination on diverse metabolites means it can illuminate previously hidden aspects of cellular regulation, paving the way for discoveries beyond sugar metabolism. This broadens the horizon immensely, promising a cascade of follow-up studies and novel biomedical applications.

The research involved international collaboration, bringing together expertise from WEHI, The University of Melbourne, the University of Cologne in Germany, and Alfred Health. Supported by prominent funding bodies such as the National Health and Medical Research Council (NHMRC), the U.S. National Institutes of Health (NIH), and the Victorian Government, this multidisciplinary effort combined cutting-edge technology with robust biological models to unravel this complex ubiquitin-glycogen interplay.

Ultimately, this study marks a pivotal moment in the field of biochemistry and metabolic research. By revealing ubiquitin’s unexpected role in direct sugar regulation, it lays the groundwork for innovative treatments that could alleviate the burden of glycogen-related diseases globally. As researchers continue to explore and exploit this mechanism, patients suffering from rare and common metabolic disorders alike may soon benefit from targeted therapies born from this revolutionary insight.

Subject of Research: Cells
Article Title: Ubiquitination of glycogen and metabolites in cells and tissues
News Publication Date: 23-Apr-2026
Web References: https://www.nature.com/articles/s41586-026-10548-x
Image Credits: WEHI
Keywords: Ubiquitination, Glycogen, Metabolism, Diabetes, Glycogen Storage Diseases, Protein Modification, NoPro-clipping, Mass Spectrometry, Cellular Regulation, Biochemistry

The DYNAMIC-III trial enrolled over 1,000 participants diagnosed with stage 3 colon cancer from Australia, New Zealand, and Canada. All patients underwent surgical resection aimed at removing the primary tumor. Approximately six weeks post-surgery, blood samples were collected for analysis of ctDNA, cancer-derived genetic fragments shed into the bloodstream through tumor cell apoptosis or necrosis. Detection of ctDNA after surgery acts as a highly sensitive biomarker for residual microscopic disease lurking beyond the reach of conventional imaging techniques.

Patients were stratified into two categories based on their ctDNA status: “low-risk” if no ctDNA was detectable, and “high-risk” if ctDNA fragments were present in circulation. This molecular categorization then guided randomized treatment allocations, comparing ctDNA-directed adjuvant chemotherapy regimens against standard chemotherapy protocols. The fundamental goal was to determine whether ctDNA testing could safely reduce overtreatment while maintaining cancer-free survival outcomes, representing a leap toward personalized medicine in colorectal oncology.

Professor Jeanne Tie from WEHI, a leading oncologist and the trial’s principal investigator, emphasizes that ctDNA-guided therapy embodies the future of precision oncology in this setting. While current guidelines advocate uniform administration of chemotherapy for all stage 3 colon cancer patients, often resulting in unnecessary exposure to cytotoxic drugs and associated toxicities, ctDNA assays can tailor treatment intensity based on molecular evidence of minimal residual disease (MRD). This nuanced approach ensures patients without detectable tumor DNA avoid the harsh side effects of chemotherapy like oxaliplatin-induced neuropathy without compromising survival chances.

The clinical data underscore the promise of this strategy. Patients categorized as ctDNA-negative post-surgery experienced remarkably favorable outcomes, with an impressive 87 percent remaining disease-free three years later. This suggests that a less aggressive chemo regimen or even omission of chemotherapy can be safe and effective in patients demonstrating molecular remission. Such precision spares patients from the physical and emotional burdens intrinsic to chemotherapy, substantially enhancing quality of life while preserving clinical efficacy.

Conversely, individuals with persistent ctDNA positivity faced a substantially elevated risk of recurrence. The study showed that only about half of these patients remained cancer-free at the three-year mark. Moreover, analysis revealed a dose-response relationship, where increasing ctDNA levels correlated with higher chances of tumor relapse. Importantly, intensification of chemotherapy in this subgroup did not improve outcomes, illuminating an urgent need for novel therapeutic strategies capable of targeting the biological pathways driving resistant or residual disease.

These findings were made possible through a seamless collaboration among several prominent organizations, including the Canadian Cancer Trials Group (CCTG), the Australasian Gastrointestinal Trials Group (AGITG), and the Peter MacCallum Cancer Centre. This multinational, multidisciplinary effort attests to the robustness and generalizability of the results, providing a strong impetus to integrate ctDNA testing into clinical oncology workflows globally.

Dr Jonathan Loree, Canadian senior investigator and DYNAMIC-III trial chair, highlights the study as the most compelling prospective evidence of ctDNA’s prognostic and predictive utility in resected stage 3 colon cancer to date. The trial’s rigorously designed randomized methodology addresses prior limitations in ctDNA research, establishing clinical validity that could fast-track incorporation into treatment guidelines. Dr Loree further stresses that these insights could also pave the way for refinements in other tumor types where MRD biomarkers hold promise.

Colorectal cancer remains a leading cause of cancer morbidity and mortality worldwide, with over 15,000 new diagnoses anticipated in Australia alone in 2024. This novel ctDNA-based liquid biopsy represents a paradigm shift, moving beyond traditional staging and histopathological factors to molecularly informed therapeutic decisions. Such advancements demonstrate how liquid biopsies, an emerging frontier in oncology, can revolutionize early detection of relapse, optimize adjuvant chemotherapy use, and ultimately improve patient survival.

The implications extend beyond clinical outcomes, promising a substantial reduction in healthcare costs and burden on patients’ lives by minimizing unnecessary treatments. By personalizing therapeutic interventions based on real-time molecular surveillance, DYNAMIC-III exemplifies how precision medicine is reshaping cancer care in the 21st century, reaffirming the critical role of translational research and international collaboration in advancing oncology.

In summary, the DYNAMIC-III trial decisively proves that ctDNA can serve as a sensitive, non-invasive biomarker to guide adjuvant chemotherapy in stage 3 colon cancer. This approach spares low-risk patients from unwarranted chemotherapy toxicity while identifying those at genuine high risk who require closer monitoring and potentially novel therapeutic approaches. As the oncology community embraces this innovation, patients stand to benefit from safer, more efficacious, and truly individualized treatment strategies that align with the molecular underpinnings of their disease.

Subject of Research: People

Article Title: Circulating Tumor DNA-Guided Adjuvant Therapy in Locally Advanced Colon Cancer: the Randomized Phase 2/3 DYNAMIC-III Trial

Web References:
10.1038/s41591-025-04030-w

Image Credits: WEHI

Keywords: Colon cancer, Cancer, Circulating tumor DNA, ctDNA, Adjuvant chemotherapy, Precision medicine, Minimal residual disease, Liquid biopsy

The essence of LoxCode lies in its ingenious use of DNA barcoding to uniquely mark each cell within a genetically engineered mouse. By inserting a library of hundreds of millions of distinct DNA sequences into the genome, the system effectively "shuffles" these sequences in a manner reminiscent of dealing cards, creating a unique barcode for every single cell. As the embryo develops, each cell inherits this distinctive barcode, which can be read later through sophisticated sequencing techniques. This approach significantly surpasses previous methods, generating a diversity of more than 30 billion unique barcodes from a remarkably compact DNA cassette composed of only 13 small DNA segments.

At the heart of this breakthrough is the ability of LoxCode to provide a lineage map at the cellular level, revealing how diverse tissues and organs arise from early embryonic cells known as the epiblast. The method grants scientists a molecular passport to track cellular progeny as they multiply, migrate, specialize, and form the myriad tissues comprising complex mammals. Until now, the challenge of following every cell’s fate during early development was insurmountable due to the sheer number and complexity of cellular differentiation pathways, but LoxCode’s barcoding offers a new era of clarity and precision.

One remarkable insight uncovered using LoxCode involves the early emergence of cell fate bias in the developing embryo. Naik and colleagues demonstrated that even in an early mass of just a few hundred cells, some cells maintain remarkable pluripotency, capable of generating every tissue type, while others already appear committed to distinct developmental trajectories destined to form certain organs such as brain, gut, limbs, or blood. These findings challenge traditional assumptions about when and how cellular commitment occurs, opening new avenues for understanding developmental timing and cellular plasticity.

The design of LoxCode is equally striking for its interdisciplinary nature, reflecting the blend of physics, synthetic biology, and computational mathematics marshaled by Dr. Tom Weber. This convergence allowed the team to engineer a DNA sequence system that maximizes diversity while minimizing genetic material and cellular disruption. The DNA barcodes can be activated and recorded in vivo in living mice, thereby preserving the natural developmental environment and avoiding the artifacts associated with in vitro studies.

Beyond its fundamental implications for developmental biology, LoxCode offers profound potential for medical research. Mapping cellular ancestry in vivo will illuminate the origins of developmental disorders, congenital defects, and diseases arising from cellular misprogramming. By pinpointing when lineage biases or aberrant differentiation events occur, researchers can better understand the molecular underpinnings of diseases and identify early intervention points.

Moreover, the system’s ability to label cells internally and decode their histories opens possibilities for regenerative medicine and cancer research. For instance, tracking how stem cells contribute to tissue repair after injury, or following the evolutionary paths of cancerous cells within tumors, can provide pivotal knowledge for designing targeted therapies and improving patient outcomes.

Already, labs around the world have begun adopting LoxCode to explore diverse biological questions—from neuronal development and immune system dynamics to organogenesis and tissue regeneration after stroke. This global uptake signals the technology’s versatility and its potential as a standard tool in cutting-edge biomedical research.

A key technical achievement of LoxCode is the sheer scale of barcode diversity achievable in situ, which outstrips prior barcoding technologies by several orders of magnitude. By generating tens of billions of unique identifiers inside living tissues, LoxCode ensures that every cell within the organism can be tracked individually, eliminating the ambiguities common to bulk analysis and population-level studies. This resolution permits the disentangling of cellular heterogeneity that defines complex biological systems.

The study detailing these advances, titled “LoxCode in vivo barcoding reveals epiblast clonal fate bias to fetal organs,” was published in the journal Cell. It includes comprehensive experimental validation using genetically engineered mouse models, illustrating the robustness and reproducibility of the barcoding technique. The DOI for this publication is 10.1016/j.cell.2025.04.026.

The availability of LoxCode mice via resource platforms such as The Jackson Laboratory ensures that the scientific community can rapidly deploy this methodology for a wide spectrum of in vivo studies, accelerating discoveries in embryology, immunology, neuroscience, and beyond.

In conclusion, LoxCode represents a tour de force in biological research tools—melding genetic engineering, molecular biology, and computational analysis into a single, versatile platform. It promises not only to unravel the fundamental mysteries of life’s early blueprint but also to inspire innovative therapies by revealing the cellular origin and evolution of health and disease. As this technology proliferates through laboratories worldwide, it is poised to catalyze a paradigm shift in how we visualize and comprehend cellular development at the most fundamental level.

Subject of Research: Animals

Article Title: LoxCode in vivo barcoding reveals epiblast clonal fate bias to fetal organs

News Publication Date: 15-May-2025

Web References:
10.1016/j.cell.2025.04.026
LoxCode mouse strain at The Jackson Laboratory

Image Credits: Credit: WEHI

Keywords: Lineage tracing, Cell development, Developmental biology